Journal article
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Abstract
\textlessh2\textgreaterSummary\textless/h2\textgreater\textlessh3\textgreaterBackground\textless/h3\textgreater\textlessp\textgreaterGlucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular …
Authors
Hernandez AF; Green JB; Janmohamed S; D Agostino RB; Granger CB; Jones NP; Leiter LA; Rosenberg AE; Sigmon KN; Somerville MC
Journal
The Lancet, Vol. 392, , pp. 1519–1529
Publication Date
10 2018
DOI
10.1016/S0140-6736(18)32261-X